Related Experiment Video
Updated: Feb 28, 2026

The Tail Suspension Test
Published on: January 28, 2012
Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling
Erinn S Gideons1, Pei-Yi Lin1, Melissa Mahgoub1
1Department of Neuroscience, UT Southwestern Medical Center, Dallas, United States.
Abstract:
Lithium is widely used as a treatment for Bipolar Disorder although the molecular mechanisms that underlie its therapeutic effects are under debate. In this study, we show brain-derived neurotrophic factor (BDNF) is required for the antimanic-like effects of lithium but not the antidepressant-like effects in mice. We performed whole cell patch clamp recordings of hippocampal neurons to determine the impact of lithium on synaptic transmission that may underlie the behavioral effects. Lithium produced a significant decrease in α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated miniature excitatory postsynaptic current (mEPSC) amplitudes due to postsynaptic homeostatic plasticity that was dependent on BDNF and its receptor tropomyosin receptor kinase B (TrkB). The decrease in AMPAR function was due to reduced surface expression of GluA1 subunits through dynamin-dependent endocytosis. Collectively, these findings demonstrate a requirement for BDNF in the antimanic action of lithium and identify enhanced dynamin-dependent endocytosis of AMPARs as a potential mechanism underlying the therapeutic effects of lithium.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Long-term Depression
Calcium Ion Concentration Mechanism
If over...
Long-term Depression
Long-term Potentiation
Long-term Potentiation
Hebbian LTP
LTP can occur when...
Bipolar Disorder

